Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Harvard Business School
Medtronic
Moodys
McKesson

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

Patent: 6,103,705

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,103,705
Title: Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
Abstract:The invention is also directed to pharmaceutical composition comprising a compound having anti-Xa activity, a platelet aggregation antagonist compound and a pharmaceutically acceptable carrier. The invention is also directed to a method of treating or preventing a thrombogenic condition associated with a thrombosis related ischemic disorder in a patient comprising administering to said patient pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound. In addition, this invention is directed to the use of pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound in the preparation of a medicament for treating or preventing a physiological condition associated with thrombosis related ischemic disorder. Furthermore, this invention is directed to a kit for treating or preventing a physiological condition associated with thrombosis related ischemic disorder, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound having anti-Xa activity and at least another of said containers contains a platelet aggregation antagonist compound, and said containers optionally contain a pharmaceutical carrier.
Inventor(s): Uzan; Andre (Paris, FR), Curaudeau; Alain H. (Devon, PA), Leadley; Robert J. (Collegeville, PA), Dunwiddie; Christopher T. (Carmel, IN), Perrone; Mark H. (Chalfont, PA)
Assignee: Aventis Pharmaceuticals Products Inc. (Collegeville, PA)
Application Number:09/192,710
Patent Claims:see list of patent claims

Details for Patent 6,103,705

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 1994-12-22 ⤷  Free Forever Trial 2016-11-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School
Medtronic
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.